Detalhe da pesquisa
1.
Trajectories of health-related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study.
Cancer
; 130(4): 609-617, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37831749
2.
Open communication between patients and relatives about illness & death in advanced cancer-results of the eQuiPe Study.
Support Care Cancer
; 32(4): 214, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38446248
3.
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol
; 19(11): 1459-1467, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30348537
4.
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Br J Cancer
; 116(11): 1415-1424, 2017 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28427087
5.
Quality of integrated female oncofertility care is suboptimal: A patient-reported measurement.
Cancer Med
; 12(3): 2691-2701, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031940
6.
Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.
J Clin Oncol
; 41(35): 5411-5421, 2023 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37639651
7.
Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer.
J Cancer Surviv
; 15(3): 380-385, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33840000
8.
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.
Ther Adv Med Oncol
; 11: 1758835919838964, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31019570
9.
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Eur J Cancer
; 107: 60-67, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30544060
10.
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
J Clin Oncol
; 34(3): 227-34, 2016 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26573078
11.
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 2(8): 1030-7, 2016 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27348762
12.
Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
Clin Cancer Res
; 9(10 Pt 2): 3995S-4002S, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14506199
13.
Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.
PLoS One
; 10(2): e0117745, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25680198
14.
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency]. / Voorkómen van ernstige toxiciteit bij chemotherapie: test op DPD-deficiëntie bij capecitabine, 5-fluorouracil en tegafur.
Ned Tijdschr Geneeskd
; 156(48): A4934, 2012.
Artigo
em Holandês
| MEDLINE | ID: mdl-23191966
15.
Ataxia telangiectasia: the consequences of a delayed diagnosis.
Radiother Oncol
; 99(1): 97-8, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21354641